MEXICO CITY, Sept. 8 /PRNewswire-FirstCall/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB) ("Genomma Lab" or "the Company"), one of the fastest growing pharmaceutical and personal care products companies in Mexico with expansion into the international markets, announced today revisions to its earnings guidance for the full year of 2009. The Company expects net sales growth in the range of 35%-38% and an EBITDA margin of approximately 25%.
The revision of the Company's expected sales growth is mainly due to the higher sales anticipated from launches of the Company's recent acquisitions, namely Primer Nivel Por tu Salud(R), combined with a positive trend in demand for our base products in Mexico and in our existing international operations.
The Company is also slightly lowering its expected EBITDA margin due to the significant advertising investment required during the first months of a product launch. Once these launches stabilize, Genomma Lab expects their profitability margins to be in line with those of the rest of its portfolio.
It is important to highlight that this guidance revision is not contemplating sales from any geographic expansion of the Company's operations.
Genomma Lab will report third quarter results on October 26, 2009 and host a quarterly conference call the following business day.
Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growing pharmaceutical and personal care products companies in Mexico with an increasing presence in the international markets. Genomma develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. Through a combination of a successful new products development process, consumer-oriented marketing, a broad retail distribution network and a low- cost, highly flexible operating model.
Genomma's shares are listed on the Mexican Stock Exchange under the ticker symbol "LAB.B" (Bloomberg: labb.mx).
Note on Forward-Looking Statements
This report may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like "believe," "anticipate," "expect," "envisages," "will likely result," or any other words or phrases of similar meaning. Such statements are subject to a number of risks, uncertainties and assumptions. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this presentation and in oral statements made by authorized officers of the Company. Readers are cautioned not to place undue reliance on these forward- looking statements, which speak only as of their dates. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact: In New York: Oscar Villalobos-Torres i-advize Corporate Communications, Inc. Tel: +52 55 5081-0000 Ext. 5106 Tel. (212) 406 3692 e-mail: email@example.com e-mail: firstname.lastname@example.org
|SOURCE Genomma Lab Internacional, S.A.B. de C.V.|
Copyright©2009 PR Newswire.
All rights reserved